Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9629853 | 0.81 | SLC6A2 (0.57) | CYP3A4ALDH1A1TSHRSMN1; SMN2ALOX15 | |
| SCHEMBL866005 | 0.81 | ALDH1A1 (0.56) | CYP3A4ALDH1A1TSHRSMN1; SMN2ALOX15 | |
| SCHEMBL30811359 | 0.81 | ALDH1A1 (0.56) | CYP3A4ALDH1A1TSHRSMN1; SMN2ALOX15 | |
| SCHEMBL110557 | 0.77 | ALDH1A1 (0.52) | CYP3A4ALDH1A1TSHRSMN1; SMN2ALOX15 | |
| SCHEMBL224672 | 0.76 | ITGB2 (0.50) | CYP3A4ALDH1A1TSHRSMN1; SMN2ALOX15 | |
| SCHEMBL3781267 | 0.74 | SLC6A2 (0.51) | CYP3A4ALDH1A1TSHRSMN1; SMN2ALOX15 | |
| SCHEMBL2850872 | 0.74 | HPGD (0.58) | CYP3A4ALDH1A1TSHRSMN1; SMN2ALOX15 | |
| SCHEMBL488913 | 0.73 | ALDH1A1 (0.37) | ALDH1A1ALOX15HPGDHSD17B10MAPK1 | |
| SCHEMBL19122057 | 0.73 | CCR2 (0.38) | CYP3A4ALDH1A1TSHRSMN1; SMN2ALOX15 | |
| SCHEMBL11206840 | 0.72 | ALDH1A1 (0.47) | CYP3A4ALDH1A1TSHRSMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119790090-A | One-component (1K) curable adhesive composition | 汉高股份有限及两合公司 | 2025-04-08 | — | — | CN | claimed |
| US-6989263-B1 | Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-01-24 | — | — | US | claimed |
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | ACHILION PHARMACEUTICALS | 2003-10-23 | — | — | US | claimed |
| WO-2003060098-A2 | METHODS FOR IDENTIFYING COMPOUNDS WHICH INHIBIT BINDING OF NUCLEOCAPSID 7 PROTEIN TO HIV-1 RNA | ACHILLION PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| EP-0782632-B1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | US GOV HEALTH & HUMAN SERV (US) | 2003-04-16 | — | — | EP | claimed |
| US-6001555-A | DISSOCIATING A ZINC FINGER BY CONTACTING THE PROTEIN WITH A DISULFIDE, A MALEIMIDE, AN ALPHA-HALOGENATED KETONE, A HYDRAZIDE, A NITRIC OXIDE OR DERIVATIVES, CUPRIC IONS, FERRIC IONS OR THEIR COMPLEXES; SYNERGISTIC EFFECTS WITH VIRICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-14 | — | — | US | claimed |
| EP-0782632-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009406-A9 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | — | 1996-05-23 | — | — | WO | claimed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | claimed |
| US-20250180952-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-06-05 | — | — | US | disclosed |
| CN-119790090-A | One-component (1K) curable adhesive composition | 汉高股份有限及两合公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-4493638-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-01-22 | — | — | EP | disclosed |
| CN-118871548-A | Photoalignment materials | 罗利克技术有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023174773-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| EP-1011729-A2 | OLIGONUCLEOTIDES WHICH SPECIFICALLY BIND RETROVIRAL NUCLEOCAPSID PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-06-28 | — | — | EP | disclosed |
| US-6001555-A | DISSOCIATING A ZINC FINGER BY CONTACTING THE PROTEIN WITH A DISULFIDE, A MALEIMIDE, AN ALPHA-HALOGENATED KETONE, A HYDRAZIDE, A NITRIC OXIDE OR DERIVATIVES, CUPRIC IONS, FERRIC IONS OR THEIR COMPLEXES; SYNERGISTIC EFFECTS WITH VIRICIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1997044064-A2 | OLIGONUCLEOTIDES WHICH SPECIFICALLY BIND RETROVIRAL NUCLEOCAPSID PROTEINS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-27 | — | — | WO | disclosed |
| EP-0782632-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services (US) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009406-A9 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | — | 1996-05-23 | — | — | WO | disclosed |
| WO-1996009406-A1 | A METHOD FOR IDENTIFYING AND USING COMPOUNDS THAT INACTIVATE HIV-1 AND OTHER RETROVIRUSES BY ATTACKING HIGHLY CONSERVED ZINC FINGERS IN THE VIRAL NUCLEOCAPSID PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030198648-A1 | Methods for identifying compounds which inhibit binding of nucleocapsid 7 protein to HIV-1 RNA | MRPS27, SNRPE, NSUN2 | CYP3A4 4653/4885ALDH1A1 4104/4885TSHR 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.